Sign Out
Synagis is indicated for the prevention of serious lower respiratory tract disease requiring hospitalisation caused by respiratory syncytial virus (RSV) in children at high risk for RSV disease: Children born at 35 weeks of gestation or less and less than 6 months of age at the onset of the RSV season.
Children less than 2 years of age and requiring treatment for bronchopulmonary dysplasia within the last 6 months.
Children less than 2 years of age and with haemodynamically significant congenital heart disease.
